With tantalizing early results, Sarepta’s gene therapy for Duchenne raises hopes for ‘real change’

An experimental gene therapy for Duchenne muscular dystrophy, licensed to Sarepta Therapeutics, produced jaw-dropping increases in a crucial muscle protein normally missing in patients with the disease, according to preliminary clinical trial data released Tuesday.